New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer

...

Related Keywords

Denmark ,London ,City Of ,United Kingdom ,United States ,San Carlos ,California ,Damsgaard ,Nordjylland ,Texas ,Laurberg ,Midtjylland ,American ,Danish ,Charles Coombes ,Imperial College London ,Clinical Laboratory Improvement Amendments ,American Cancer Society ,Natera Inc ,Nasdaq ,Danish Breast Cancer Group ,Exploratory Breast Lead Interval Study ,Minetta Liu ,Cancer Facts ,Breast Cancer ,Natl Compr Canc ,Practice Guidelines ,Ann Oncol ,